肿瘤标志物在非小细胞肺癌复发检验中的应用效果分析  

Analysis of the Application Effects of Tumor Markers in Detecting Recurrence of Non-Small Cell Lung Cancer

作　　者：张双霞 ZHANG Shuangxia(Department of Medical Laboratory,Yongmei Group General Hospital,Yongcheng Henan 476600,China)

机构地区：[1]永煤集团总医院医学检验科,河南永城476600

出　　处：《临床研究》2025年第1期139-142,共4页Clinical Research

摘　　要：目的分析肿瘤标志物在非小细胞肺癌复发检验中的应用效果。方法纳入永煤集团总医院2022年3月至2024年6月的72例非小细胞肺癌患者为研究样本。根据病理分型将患者分为42例肺腺癌患者与30例肺鳞癌患者。所有患者入院后均接受血清肿瘤标志物检查,检查标志物包括鳞状细胞癌相关抗原(SCCA)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)。所有患者均接受临床对症治疗,对比42例肺腺癌患者与30例肺鳞癌患者治疗前、治疗1月后上述指标变化情况。后对患者进行随访,根据疾病复发情况将患者分为肺腺癌复发组(20例)、肺腺癌未复发组(22例)、肺鳞癌复发组(18例)、肺鳞癌未复发组(12例),对比复发患者、未复发患者SCCA、CYFRA21-1、CEA测值。结果肺腺癌治疗1月后CYFRA21-1、CEA测值均低于治疗前,差异均有统计学意义(P<0.05),SCCA对比差异无统计学意义(P>0.05);肺鳞癌治疗1月后SCCA、CYFRA21-1测值均低于治疗前,差异均有统计学意义(P<0.05),CEA对比差异无统计学意义(P>0.05);肺腺癌复发组CYFRA21-1、CEA测值均高于肺腺癌未复发组,差异均有统计学意义(P<0.05),SCCA对比差异无统计学意义(P>0.05);肺鳞癌复发组SCCA、CYFRA21-1测值均高于肺鳞癌未复发组,差异均有统计学意义(P<0.05),CEA对比差异无统计学意义(P>0.05)。结论肿瘤标志物在非小细胞肺癌复发检验中具有较高的应用价值,可为疾病是否复发提供一定参考依据。Objective To analyze the effects of tumor markers in the detection of recurrence in patients with non-small cell lung cancer.Methods A total of 72 patients with non-small cell lung cancer admitted to Yongmei Group General Hospital from March 2022 to June 2024 were included in this study.Based on pathological classification,patients were divided into two groups:42 patients with lung adenocarcinoma and 30 patients with lung squamous cell carcinoma.All patients underwent serum tumor marker testing after admission,and the tested markers included squamous cell carcinoma antigen(SCCA),cytokeratin 19 fragment(CYFRA21-1),and carcinoembryonic antigen(CEA).All patients received clinical symptomatic treatment,and changes in the above indicators were compared between the lung adenocarcinoma and lung squamous cell carcinoma groups before treatment and 1 month after treatment.Patients were then followed up,and based on disease recurrence,the patients were divided into a lung adenocarcinoma recurrence group(20 cases),a lung adenocarcinoma non-recurrence group(22 cases),a lung squamous cell carcinoma recurrence group(18 cases),and a lung squamous cell carcinoma non-recurrence group(12 cases).The SCCA,CYFRA21-1,and CEA levels were compared between recurrence and non-recurrence patients.Results In the lung adenocarcinoma group,the CYFRA21-1 and CEA levels after 1 month of treatment were significantly lower than those before treatment(P<0.05),while the SCCA levels showed no significant difference(P>0.05).In the lung squamous cell carcinoma group,both SCCA and CYFRA21-1 levels decreased after 1 month of treatment,with statistically significant differences(P<0.05),while CEA showed no significant difference(P>0.05).The CYFRA21-1 and CEA levels in the lung adenocarcinoma recurrence group were significantly higher than those in the non-recurrence group(P<0.05),while the SCCA levels showed no significant difference(P>0.05).In the lung squamous cell carcinoma recurrence group,SCCA and CYFRA21-1 levels were significantly higher than in the

关 键 词：肿瘤标志物 非小细胞肺癌 复发 检验 

分 类 号：R734.2[医药卫生—肿瘤]